PharmaEssentia Toekomstige groei

Future criteriumcontroles 5/6

PharmaEssentia zal naar verwachting groeien in winst en omzet met respectievelijk 92% en 40.4% per jaar. De winst per aandeel zal naar verwachting groeien met 91.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 19% zijn.

Belangrijke informatie

92.0%

Groei van de winst

91.1%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	40.4%
Toekomstig rendement op eigen vermogen	19.0%
Dekking van analisten	Low
Laatst bijgewerkt	25 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

BDL:261280558 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (TWD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	20,526	N/A	N/A	N/A	2
12/31/2025	14,724	5,835	2,862	4,887	4
12/31/2024	9,557	2,689	2,020	3,335	2
9/30/2024	8,320	1,846	417	1,537	N/A
6/30/2024	6,913	1,325	-138	897	N/A
3/31/2024	5,871	442	-1,426	-274	N/A
12/31/2023	5,106	-624	-2,033	-706	N/A
9/30/2023	4,300	-890	-1,867	-1,113	N/A
6/30/2023	3,805	-1,498	-2,318	-1,549	N/A
3/31/2023	3,518	-1,569	-2,063	-1,436	N/A
12/31/2022	2,882	-1,375	-1,826	-1,505	N/A
9/30/2022	2,420	-2,111	-1,822	-1,572	N/A
6/30/2022	1,702	-2,403	-2,160	-2,068	N/A
3/31/2022	811	-2,669	-2,597	-2,531	N/A
12/31/2021	657	-2,811	-2,560	-2,462	N/A
9/30/2021	569	-2,756	-2,814	-2,657	N/A
6/30/2021	610	-2,673	-2,643	-2,440	N/A
3/31/2021	654	-2,340	-2,215	-2,019	N/A
12/31/2020	557	-1,948	-1,663	-1,455	N/A
9/30/2020	464	-1,204	-1,266	-1,020	N/A
6/30/2020	332	-862	-1,053	-845	N/A
3/31/2020	271	-856	-1,077	-844	N/A
12/31/2019	306	-843	-1,151	-945	N/A
9/30/2019	130	-1,113	-978	-836	N/A
6/30/2019	129	-1,080	-1,099	-919	N/A
3/31/2019	61	-1,086	-1,067	-899	N/A
12/31/2018	26	-1,040	-978	-827	N/A
9/30/2018	4	-930	-940	-823	N/A
6/30/2018	4	-882	N/A	-749	N/A
3/31/2018	4	-878	N/A	-755	N/A
12/31/2017	4	-872	N/A	-790	N/A
9/30/2017	4	-862	N/A	-750	N/A
6/30/2017	5	-898	N/A	-762	N/A
3/31/2017	6	-904	N/A	-696	N/A
12/31/2016	5	-845	N/A	-657	N/A
9/30/2016	7	-892	N/A	-685	N/A
6/30/2016	9	-865	N/A	-628	N/A
3/31/2016	11	-870	N/A	-579	N/A
12/31/2015	12	-853	N/A	-527	N/A
9/30/2015	9	-819	N/A	-556	N/A
6/30/2015	9	-804	N/A	-567	N/A
3/31/2015	9	-796	N/A	-601	N/A
12/31/2014	13	-853	N/A	-599	N/A
9/30/2014	17	-812	N/A	-470	N/A
6/30/2014	19	-833	N/A	-448	N/A
3/31/2014	46	-713	N/A	-367	N/A
12/31/2013	72	-593	N/A	-285	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 261280558 ( 92% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van 261280558 ( 92% per jaar) zal naar verwachting sneller groeien dan de Luxembourg markt ( 13.9% per jaar).

Hoge groeiwinsten: De winst van 261280558 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 261280558 ( 40.4% per jaar) zal naar verwachting sneller groeien dan de markt Luxembourg ( 4.8% per jaar).

Hoge groei-inkomsten: De omzet van 261280558 ( 40.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 261280558 zal naar verwachting over 3 jaar laag zijn ( 19 %).

PharmaEssentia Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

PharmaEssentia Corporation Announces Nine Data Presentations at ASH Annual Meeting

PharmaEssentia Corporation to Report Q3, 2024 Results on Nov 14, 2024

PharmaEssentia Corporation Announces Positive Recommendation from the DSMB to Continue the Phase III Clinical Trial of Ropeginterferon Alfa-2b for Essential Thrombocythemia (ET)

PharmaEssentia Corporation Announces Taiwan MOHW Approves IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors in Principle

PharmaEssentia Corporation to Report Q2, 2024 Results on Aug 13, 2024

PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors

Pharmaessentia Corporation Announces Appointments to Board of Directors

Pharmaessentia Corporation Announces Changes to Members of Third Audit Committee

PharmaEssentia Corporation Provides an Update on Submission of P1101 PhaseIII Clinical Study Protocol for Pre-fibrotic/Early PMFor Overt PMF at Low to Intermediate-1 Risk to China NMPA

PharmaEssentia Corporation to Report Q1, 2024 Results on May 13, 2024

PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA

PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia

PharmaEssentia Corporation announced a financing transaction

PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA

PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA

PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia

Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B (P1101) for the Treatment of PV in China

PharmaEssentia Corporation Receives Civil Lawsuit Decision from Middlesex Superior Court for the Commonwealth of Massachusetts

PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as Besremi®) for the Treatment of Patients with Polycythemia Vera (PV)

PharmaEssentia Corp. Announces Submission of New Drug Registration of BESREMi (Ropeginterferon Alfa-2b) for PV in Hong Kong

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven